Total Payments
$970,936
2024 Payments
$83,288
Companies
13
Transactions
1,005
Medicare Patients
859
Medicare Billing
$134,169
Payment Breakdown by Category
Other$560,109 (57.7%)
Consulting$199,171 (20.5%)
Travel$147,725 (15.2%)
Research$44,602 (4.6%)
Food & Beverage$19,321 (2.0%)
Education$8.62 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $542,369 | 230 | 55.9% |
| Consulting Fee | $199,171 | 55 | 20.5% |
| Travel and Lodging | $147,725 | 432 | 15.2% |
| Unspecified | $44,602 | 8 | 4.6% |
| Food and Beverage | $19,321 | 265 | 2.0% |
| Honoraria | $13,900 | 12 | 1.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,840 | 2 | 0.4% |
| Education | $8.62 | 1 | 0.0% |
Payments by Type
General
$926,335
997 transactions
Research
$44,602
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $308,941 | 357 | $0 (2024) |
| Shire North American Group Inc | $214,623 | 210 | $0 (2019) |
| Radius Health, Inc. | $184,480 | 264 | $0 (2024) |
| Ascendis Pharma Inc | $127,109 | 130 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $74,030 | 16 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $38,750 | 6 | $0 (2021) |
| Merck Sharp & Dohme LLC | $5,894 | 7 | $0 (2023) |
| Ipsen Innovation | $4,965 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $4,479 | 6 | $0 (2024) |
| Novo Nordisk Inc | $3,250 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $83,288 | 113 | Amgen Inc. ($57,172) |
| 2023 | $147,626 | 178 | Ascendis Pharma Inc ($91,950) |
| 2022 | $95,246 | 98 | Amgen Inc. ($37,622) |
| 2021 | $63,608 | 37 | Amgen Inc. ($24,498) |
| 2020 | $84,734 | 50 | Amgen Inc. ($37,247) |
| 2019 | $221,212 | 188 | Shire North American Group Inc ($99,822) |
| 2018 | $178,922 | 231 | Radius Health, Inc. ($102,740) |
| 2017 | $96,301 | 110 | Shire North American Group Inc ($67,050) |
All Payment Transactions
1,005 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | EVENITY (Biological) | Consulting Fee | Cash or cash equivalent | $1,490.00 | General |
| Category: Bone Health | ||||||
| 12/17/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Bone Health | ||||||
| 12/12/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Bone Health | ||||||
| 12/12/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $367.00 | General |
| Category: Bone Health | ||||||
| 12/11/2024 | Ascendis Pharma Inc | Yorvipath (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,164.00 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Bone Health | ||||||
| 12/11/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $367.00 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | In-kind items and services | $497.33 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $40.20 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $16.56 | General |
| Category: Bone Health | ||||||
| 12/09/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $109.75 | General |
| Category: Bone Health | ||||||
| 12/05/2024 | Ascendis Pharma Inc | Yorvipath (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,582.00 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $119.03 | General |
| Category: Bone Health | ||||||
| 11/21/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Bone Health | ||||||
| 11/21/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $367.00 | General |
| Category: Bone Health | ||||||
| 11/20/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Bone Health | ||||||
| 11/15/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | In-kind items and services | $678.00 | General |
| Category: Bone Health | ||||||
| 11/14/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $128.82 | General |
| Category: Bone Health | ||||||
| 11/06/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Bone Health | ||||||
| 11/06/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $367.00 | General |
| Category: Bone Health | ||||||
| 11/05/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $35.64 | General |
| Category: Bone Health | ||||||
| 11/05/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $18.30 | General |
| Category: Bone Health | ||||||
| 10/31/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $35.64 | General |
| Category: Bone Health | ||||||
| 10/31/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $18.30 | General |
| Category: Bone Health | ||||||
| 10/30/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $115.15 | General |
| Category: Bone Health | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | Regeneron Pharmaceuticals, Inc. | $27,375 | 4 |
| A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva | Regeneron Pharmaceuticals, Inc. | $11,375 | 2 |
| 601090: Natpara Next Generation Usability Evaluation | Takeda Pharmaceuticals U.S.A., Inc. | $4,680 | 1 |
| Ph3 PMO Fracture Study | Amgen Inc. | $1,172 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 239 | 269 | $202,310 | $41,830 |
| 2022 | 3 | 230 | 271 | $198,920 | $40,293 |
| 2021 | 5 | 251 | 270 | $160,380 | $37,614 |
| 2020 | 2 | 139 | 150 | $66,020 | $14,432 |
Total Patients
859
Total Services
960
Medicare Billing
$134,169
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 204 | 234 | $173,160 | $35,271 | 20.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $29,150 | $6,559 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 172 | 209 | $154,660 | $31,419 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $31,540 | $6,548 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 24 | $12,720 | $2,326 | 18.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 144 | 158 | $106,800 | $25,927 | 24.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $25,730 | $6,012 | 23.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 57 | $26,410 | $5,540 | 21.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 11 | 12 | $1,440 | $135.10 | 9.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 11 | 12 | $0.12 | $0.10 | 83.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 120 | 131 | $56,330 | $11,955 | 21.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 19 | 19 | $9,690 | $2,477 | 25.6% |
About Dr. John Bilezikian, M.D
Dr. John Bilezikian, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275600975.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Bilezikian, M.D has received a total of $970,936 in payments from pharmaceutical and medical device companies, with $83,288 received in 2024. These payments were reported across 1,005 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($542,369).
As a Medicare-enrolled provider, Bilezikian has provided services to 859 Medicare beneficiaries, totaling 960 services with total Medicare billing of $134,169. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location New York, NY
- Active Since 11/29/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1275600975
Products in Payments
- Tymlos (Biological) $168,981
- Prolia (Biological) $164,440
- EVENITY (Biological) $110,258
- NATPARA (Drug) $103,956
- NATPARA (PARATHYROID HORMONE) (Drug) $85,894
- Tymlos (Drug) $14,034
- Repatha (Biological) $11,559
- SKYTROFA (Drug) $6,338
- Yorvipath (Drug) $4,746
- STRENSIQ (Biological) $4,479
- IMLYGIC (Biological) $4,000
- XGEVA (Biological) $2,000
- IQIRVO (Drug) $1,125
- Neulasta (Biological) $1,100
- PYRUKYND (Drug) $1,000
- Skytrofa (Drug) $124.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in New York
Anastasios Manessis, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $719,303
Endocrinology, Diabetes & Metabolism $719,303
Stuart Weiss, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $520,227
Endocrinology, Diabetes & Metabolism $520,227
Dr. Brian Levy, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $383,360
Endocrinology, Diabetes & Metabolism $383,360
Recaredo Berbano, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $340,374
Endocrinology, Diabetes & Metabolism $340,374
Dr. Jason Baker, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $308,409
Endocrinology, Diabetes & Metabolism $308,409
Dr. Henry Ginsberg, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $291,638
Endocrinology, Diabetes & Metabolism $291,638